Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 287–288.

https://doi.org/10.1182/blood-2022-159357

Published: 2022

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial

Ulrich Duehrsen, MD, Stefan P Müller, MD, Jan Rekowski, Dipl.-Stat., Bernd Hertenstein, MD, Christiane Franzius, MD, Rolf Mesters, MD, Matthias Weckesser, MD, Frank Kroschinsky, MD, Jörg Kotzerke, MD, Anke Franzke, MD, Frank M Bengel, MD, Paul La Rosée, MD, Martin Freesmeyer, MD, Heinz-Gert Hoeffkes, MD, Andreas Hertel, MD, Dirk Behringer, Gabriele Prange-Krex, MD, Martin Griesshammer, MD, Jens Holzinger, MD, Stefan Wilop, MD, Thomas Krohn, MD, Aruna Raghavachar, MD, Georg Maschmeyer, MD, Ingo Brink, MD, Roland Schroers, MD, Tobias Gaska, MD, Tu-Anh Dang, MD, Aristoteles Giagounidis, Ariane Dienst, MD, Hubertus Hautzel, MD, Ralph Naumann, MD, Alfred Klein, MD, Dennis Hahn, MD, Gabriele Pöpperl, MD, Matthias Grube, MD, Jörg Marienhagen, MD, Andreas Schwarzer, MD, Lars Kurch, MD, Thomas Höhler, MD, Heike Steiniger, MD, Holger Nückel, MD, Thomas Südhoff, MD, Wolfgang Römer, MD, Marcus Brinkmann, Claudia Ose, Dieter Hoelzer, MD, Jan Dürig, MD, Karl-Heinz Jöckel, PhD, Wolfram Klapper, MD, Andreas Hüttmann, MD

Blood (2016) 128 (22): 1857.

https://doi.org/10.1182/blood.V128.22.1857.1857

Published: 2016

Journal Articles

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood (2013) 122 (21): 368.

https://doi.org/10.1182/blood.V122.21.368.368

Published: 2013

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

Albrecht Reichle, Christina Hart, Matthias Grube, Reinhard Andreesen

Blood (2012) 120 (21): 5029.

https://doi.org/10.1182/blood.V120.21.5029.5029

Published: 2012

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

Journal Articles

Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)

Blood (2010) 116 (21): 2395.

https://doi.org/10.1182/blood.V116.21.2395.2395

Published: 2010

Journal Articles

Identification of Novel MHC Class I and Class II Epitopes of WT1 Using a Peptide Library Screen.

Katayoun Rezvani, MD, PhD, Stephan Mielke, MD, Yasemin Kilical, Matthias Grube, MD, Hiroshi Fujiwara, MD, Giuseppe Sconocchia, MD, Jongming Lee, MD, PhD, Frank El-Ouriaghi, MD, Nancy Hensel, A. John Barrett, MD

Blood (2005) 106 (11): 2764.

https://doi.org/10.1182/blood.V106.11.2764.2764

Published: 2005

Journal Articles

Is Survivin a Possible Target Antigen for Cellular Immunotherapy in Multiple Myeloma?.

Matthias Grube, MD, Stephanie Moritz, Ellen Obermann, MD, Katayoun Rezvani, MD, PhD, Andreas Mackensen, MD, PhD, Reinhard Andreesen, MD, PhD, Ernst Holler, MD, PhD

Blood (2005) 106 (11): 5145.

https://doi.org/10.1182/blood.V106.11.5145.5145

Published: 2005

Journal Articles

T Cell Responses Directed Against HLA A*0201-Restricted Epitopes Derived from WT1 Are Readily Identifiable in Patients with AML and CML, but Not in Patients with ALL.

Katayoun Rezvani, M.D., Jason Brenchley, M.D., David Price, M.D., Yasemin Kilical, Matthias Grube, M.D., Emma Gostick, M.D, Yong Tang, M.D., Giuseppe Sconocchia, M.D., Hiroshi Fujiwara, M.D., Elaine Sloand, M.D, Daniel C. Douek, M.D., John Barrett, M.D

Blood (2004) 104 (11): 2526.

https://doi.org/10.1182/blood.V104.11.2526.2526

Published: 2004

Journal Articles

In Vitro Induction of Myeloid Leukemia Specific CD4 and CD8 T-Cells by CD40 Ligand Activated B Cells Gene-Modified to Express Primary Granule Proteins.

Hiroshi Fujiwara, MD, PhD, Joseph J. Melenhorst, PhD, Frank El Ouriaghli, Sachiko Kajigaya, PhD, Matthias Grube, MD, Giuseppe Sconocchia, MD, Katayoun Rezvani, MD, David A. Price, PhD, Nancy F. Hensel, Daniel C. Douek, MD, A. John Barrett, MD

Blood (2004) 104 (11): 1351.

https://doi.org/10.1182/blood.V104.11.1351.1351

Published: 2004

Journal Articles

Identification and in vitro expansion of CD4 + and CD8 + T cells specific for human neutrophil elastase

Hiroshi Fujiwara, Frank El Ouriaghli, Matthias Grube, David A. Price, Katayoun Rezvani, Emma Gostick, Giuseppe Sconocchia, Jos Melenhorst, Nancy Hensel, Daniel C. Douek, A. John Barrett

Blood (2004) 103 (8): 3076–3083.

https://doi.org/10.1182/blood-2003-07-2424

Published: 2004

Journal Articles

Functional leukemia-associated antigen-specific memory CD8 + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation

Katayoun Rezvani, Matthias Grube, Jason M. Brenchley, Giuseppe Sconocchia, Hiroshi Fujiwara, David A. Price, Emma Gostick, Ko Yamada, Jan Melenhorst, Richard Childs, Nancy Hensel, Daniel C. Douek, A. John Barrett

Blood (2003) 102 (8): 2892–2900.

https://doi.org/10.1182/blood-2003-01-0150

Published: 2003

NARROW

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - Interim PET-Based Outcome Prediction and Treatment Changes in Patients with B Cell Lymphomas Participating in the PETAL Trial

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)

Identification of Novel MHC Class I and Class II Epitopes of WT1 Using a Peptide Library Screen.

Is Survivin a Possible Target Antigen for Cellular Immunotherapy in Multiple Myeloma?.

T Cell Responses Directed Against HLA A*0201-Restricted Epitopes Derived from WT1 Are Readily Identifiable in Patients with AML and CML, but Not in Patients with ALL.

In Vitro Induction of Myeloid Leukemia Specific CD4 and CD8 T-Cells by CD40 Ligand Activated B Cells Gene-Modified to Express Primary Granule Proteins.

Identification and in vitro expansion of CD4 + and CD8 + T cells specific for human neutrophil elastase

Functional leukemia-associated antigen-specific memory CD8 + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only